Crohn's disease

46 trials 19 recruiting MedDRA PT
46 Registered trials
19 Recruiting
29 Unique sponsors
29 Unique IMPs
33 Commercial trials
Drug classes (ATC)
— ATC code not specified 32
L Oncology (ATC L) 14
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 19 substances
JAK inhibitor 3 substances
Monoclonal antibody (humanized) 3 substances
Monoclonal antibody 1 substance
Monoclonal antibody (human) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase III: 15 Phase II/III: 3 Phase II: 14 Phase I/II: 1 Phase III/IV: 3 Phase IV: 6 Phase I: 1 Phase I (Other): 1 Other: 3

Filter these 46 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 46 trials

Phase III

15 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    RISANKIZUMAB
    2022-502050-14-00 10 countries 2024 n=59
    Recruiting
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2023-504951-29-00 19 countries 2017 n=229
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    RISANKIZUMAB
    2023-506399-28-00 22 countries 2017 n=387
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    RISANKIZUMAB
    2024-516023-13-00 4 countries 2025 n=31
    Ended
  • Celgene Corp. Commercial
    OZANIMOD
    2023-510426-33-00 14 countries 2018 n=351
    Ended
  • Celgene International II SARL Commercial
    OZANIMOD
    2024-511553-22-00 15 countries 2018 n=462
    Ended
  • Eli Lilly & Co. Commercial
    MIRIKIZUMAB
    2024-511472-32-00 9 countries 2024 n=30
    Ended
  • Janssen - Cilag International Commercial
    USTEKINUMAB
    2022-501067-40-00 7 countries 2021 n=83
    Ended
  • Janssen - Cilag International Commercial
    GUSELKUMAB
    2023-504040-34-01 8 countries 2024 n=151
    Ended
  • Janssen - Cilag International Commercial
    GUSELKUMAB
    2023-504735-41-00 9 countries 2024 n=30
    Recruiting
  • Janssen - Cilag International Commercial
    GUSELKUMAB
    2023-504737-41-00 10 countries 2022 n=219
    Ended
  • Janssen - Cilag International Commercial
    USTEKINUMAB
    2023-504978-38-00 4 countries 2021 n=60
    Ended
  • Janssen - Cilag International Commercial
    GUSELKUMAB
    2023-509560-16-00 8 countries 2024 n=85
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    VEDOLIZUMAB
    2023-503188-40-00 10 countries 2025 n=30
    Recruiting
  • Centre Medico Chirurgical Ambroise Pare Hartmann Academic
    INFLIXIMAB
    2023-508584-72-00 1 country 2024 n=130
    Ended

Phase II/III

3 trials
  • Arena Pharmaceuticals Inc. Commercial
    ETRASIMOD ARGININE
    2024-513569-38-00 15 countries 2021 n=367
    Ended
  • Celgene Corp. Commercial
    OZANIMOD; OZANIMOD, OZANIMOD
    2023-508777-91-00 6 countries 2023 n=50
    Ended
  • Janssen - Cilag International Commercial
    GUSELKUMAB; USTEKINUMAB
    2023-504736-18-00 13 countries 2018 n=474
    Ended

Phase II

14 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ABBV-8736; HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST ALFA4BETA7 INTEGRIN; LUTIKIZUMAB; RISANKIZUMAB
    2024-513009-30-00 23 countries 2024 n=572
    Recruiting
  • Abivax Commercial
    OBEFAZIMOD
    2023-508234-34-00 11 countries 2025 n=139
    Recruiting
  • Agomab Spain S.L. Commercial
    ORG-129
    2022-502789-26-01 6 countries 2023 n=63
    Ended
  • AstraZeneca AB Commercial
    AZD7798
    2024-514407-33-00 5 countries 2024 n=27
    Ended
  • Boehringer Ingelheim International GmbH Commercial
    BI 706321; USTEKINUMAB
    2024-512756-38-00 6 countries 2022 n=27
    Ended
  • F. Hoffmann-La Roche AG Commercial
    PF-06480605; RO7790121
    2023-504265-23-00 11 countries 2023 n=70
    Recruiting
  • Morphic Therapeutic Inc. Commercial
    MORF-057
    2023-508158-24-00 12 countries 2024 n=199
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    BALINATUNFIB
    2024-512633-32-00 11 countries 2025 n=193
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    ZASOCITINIB
    2023-506704-14-00 14 countries 2024 n=127
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    VEDOLIZUMAB
    2023-507766-35-00 2 countries 2018 n=36
    Ended
  • Centre Hospitalier Regional De Marseille Academic
    AUTOLOGOUS ADIPOSE TISSUE-DERIVED STROMAL VASCULAR FRACTION CELLS; SODIUM CHLORIDE, HUMAN SERUM ALBUMIN 5%
    2024-517794-24-00 1 country 2024 n=84
    Recruiting
  • Medibiofarma S.L. Academic
    MBF-118
    2022-501464-18-00 1 country 2023 n=10
    Ended
  • Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy Academic
    IMP not specified
    2023-506626-37-00 1 country 2025 n=192
    Recruiting
  • Medibiofarma S.L. Academic
    MBF-118
    2022-501464-18-00 1 country 2023 n=10
    Ended

Phase I/II

1 trial
  • Klinikum der Universitaet Muenchen AöR Academic
    INTESTIFIX
    2022-503027-10-00 1 country 2025 n=24
    Recruiting

Phase III/IV

3 trials
  • Takeda Development Center Americas Inc. Commercial
    UPADACITINIB; VEDOLIZUMAB
    2023-509391-42-00 18 countries 2025 n=224
    Recruiting
  • Assistance Publique Hopitaux De Paris Academic
    ALLOGENEIC FAECAL MICROBIOTA, POOLED; PLACEBO
    2024-511822-30-00 1 country 2021 n=350
    Recruiting
  • Belgian IBD Research and Development Academic
    USTEKINUMAB
    2024-514326-23-00 1 country 2021 n=108
    Ended

Phase IV

6 trials
  • Alimentiv Inc. Commercial
    VEDOLIZUMAB
    2023-509096-16-00 8 countries 2024 n=191
    Recruiting
  • Amsterdam UMC Academic
    IMP not specified
    2023-505317-25-00 1 country 2023 n=10
    Recruiting
  • Amsterdam UMC Stichting Academic
    VEDOLIZUMAB
    2024-514740-82-00 1 country 2025 n=278
    Recruiting
  • Belgian IBD Research and Development Academic
    IMP not specified
    2023-508166-15-00 1 country 2024 n=275
    Ended
  • Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif Academic
    INFLIXIMAB
    2023-508242-18-00 3 countries 2021 n=185
    Ended
  • UZ Leuven Academic
    GUSELKUMAB; MIRIKIZUMAB
    2022-500311-39-00 2 countries 2022 n=352
    Recruiting

Phase I

1 trial
  • Exeliom Biosciences Commercial
    IMP not specified
    2022-502241-99-00 2 countries 2023 n=50
    Ended

Phase I (Other)

1 trial
  • Pfizer Inc. Academic
    RITLECITINIB TOSILATE
    2022-502872-22-00 1 country 2023 n=12
    Ended

Other

3 trials
  • Sun Pharmaceutical Industries Limited Commercial
    IMP not specified
    2024-512770-10-00 1 country 2024 n=50
    Ended
  • Sun Pharmaceutical Industries Limited Commercial
    IMP not specified
    2024-512771-12-00 1 country 2024 n=32
    Ended
  • Sun Pharmaceutical Industries Limited Commercial
    IMP not specified
    2024-512773-27-00 1 country 2024 n=54
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Janssen - Cilag International Commercial 7 Phase II/III, Phase III 2
AbbVie Deutschland GmbH & Co. KG Commercial 5 Phase II, Phase III 2
Takeda Development Center Americas Inc. Commercial 4 Phase III/IV, Phase II, Phase III 3
Sun Pharmaceutical Industries Limited Commercial 3 Other 0
Celgene Corp. Commercial 2 Phase II/III, Phase III 0
Belgian IBD Research and Development Academic 2 Phase III/IV, Phase IV 0
Medibiofarma S.L. Academic 2 Phase II 0
Exeliom Biosciences Commercial 1 Phase I 0
Arena Pharmaceuticals Inc. Commercial 1 Phase II/III 0
Abivax Commercial 1 Phase II 1
Agomab Spain S.L. Commercial 1 Phase II 0
AstraZeneca AB Commercial 1 Phase II 0
Boehringer Ingelheim International GmbH Commercial 1 Phase II 0
F. Hoffmann-La Roche AG Commercial 1 Phase II 1
Morphic Therapeutic Inc. Commercial 1 Phase II 1
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II 1
Celgene International II SARL Commercial 1 Phase III 0
Eli Lilly & Co. Commercial 1 Phase III 0
Alimentiv Inc. Commercial 1 Phase IV 1
Assistance Publique Hopitaux De Paris Academic 1 Phase III/IV 1
New trials by year
2021
6
2022
3
2023
8
2024
16
2025
8
← All indication landscapes